Our readers have been curious whether there will be any "pure-play hemp" IPOs on the horizon. Today we're going to tell you why that's not likely - and how to unlock the most significant gains the cannabis industry has to offer.
Whenever a hot sector comes under some near-term pressure, the shorts - investors who essentially bet a stock will go down - come out to play. They're not always right or even well-meaning in their intentions. But not all of them are wrong, either.
Where stocks trade typically tells you a lot about how established a company is. It says something about the kind of resources the company has to report to regulators and its developed financial strength. But many of cannabis' greatest opportunities are not on the NYSE or Nasdaq.
Whether a first time trader or a somewhat seasoned investor who just wants to make sure the information they believe is accurate about trading actually is, there is always value in reviewing the basics of cannabis investing and the tools available.
As alcohol Prohibition ended 86 years ago today, illicit revenue became legal profits available to savvy investors, a flood of researched-based innovation drove new products, and the industry soared. This is all happening in the cannabis industryright now.
Epidolex may be the first FDA-approved, cannabis-based pharma product on the market. But over-the-counter, hemp-based CBD products will take a large bite out of that market as it continues to show similar effects as the price, prescription-based brand.
Not all IPOs are created equal. The biggest winners, the next Tilray, are going to thrive in at least one of three key areas of focus. These are areas where companies can truly differentiate themselves from the crowd.